Janine Haslett
L.K. Stamp
Christchurch, CAN, New Zealand
Christchurch, CAN, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation.
Journal: The Journal of rheumatology
Published: July 15, 2026
Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system.
Journal: Annals of the rheumatic diseases
Published: November 09, 2025
The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective Dosing.
Journal: Clinical pharmacokinetics
Published: July 10, 2025
Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia.
Journal: Arthritis care & research
Published: April 08, 2025
Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis.
Journal: Arthritis care & research
Published: December 15, 2024
Incidence, prevalence and mortality of rheumatoid arthritis in Canterbury, Aotearoa New Zealand.
Journal: Internal medicine journal
Published: October 18, 2024
Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy.
Journal: Arthritis care & research
Published: January 09, 2024
The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools).
Journal: British journal of clinical pharmacology
Published: November 29, 2023
Rheumatoid interstitial lung disease in Canterbury, Aotearoa New Zealand - A retrospective cohort study.
Journal: Seminars in arthritis and rheumatism
Published: September 11, 2023
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Journal: Annals of the rheumatic diseases
Published: July 17, 2023
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.
Journal: Annals of the rheumatic diseases
Published: June 14, 2023
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 08, 2023
Last Updated: 09/26/2026